CytoSorb receives approval to treat elevated bilirubin in Europe

CytoSorbents received European Union regulatory approval to expand the use of CytoSorb to reduce elevated bilirubin and myoglobin from blood, according to a press release.

“This label expansion has the potential to significantly increase the total worldwide addressable market for CytoSorb,” Vincent Capponi, chief operating officer of CytoSorbents, said in the release. “Critical care physicians now have a new therapy to rapidly reduce high levels of bilirubin frequently associated with chronic liver disease and liver failure, and elevated myoglobin associated with accidents and traumatic injury.”

The CytoSorb blood purification technology is based on biocompatible, highly porous polymer beads that actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorb has previously been used to treat deadly inflammation and cardiac surgery patients.

“These are diseases that afflict millions of people worldwide each year, where the simultaneous reduction of excessive cytokines, bilirubin, and/or myoglobin by CytoSorb can be beneficial,” Capponi said in the release. “Where possible, we plan to continue expanding the CytoSorb label to bring our therapy to those in greatest need.” – by Talitha Bennett

Reference: www.cytosorbents.com